BR112021023834A2 - Inibidores de dopamina-b-hidroxilase - Google Patents

Inibidores de dopamina-b-hidroxilase

Info

Publication number
BR112021023834A2
BR112021023834A2 BR112021023834A BR112021023834A BR112021023834A2 BR 112021023834 A2 BR112021023834 A2 BR 112021023834A2 BR 112021023834 A BR112021023834 A BR 112021023834A BR 112021023834 A BR112021023834 A BR 112021023834A BR 112021023834 A2 BR112021023834 A2 BR 112021023834A2
Authority
BR
Brazil
Prior art keywords
compounds
solvates
hydroxylase inhibitors
dopamine
salts
Prior art date
Application number
BR112021023834A
Other languages
English (en)
Other versions
BR112021023834A8 (pt
Inventor
Alexander Beliaev
Francisco Cardona
Laszlo Kiss
Soares Da Silva Patricio
Rui Pinto
Tino Rossi
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of BR112021023834A2 publication Critical patent/BR112021023834A2/pt
Publication of BR112021023834A8 publication Critical patent/BR112021023834A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores de dopamina-beta-hidroxilase. a presente invenção refere-se a: (a) compostos de fórmula i (com r1 a r5 e a como aqui definidos) e sais ou solvatos farmaceuti-camente aceitáveis do mesmo que são úteis como inibidores de do-pamina-beta-hidroxilase; (b) composições farmacêuticas compreendendo esses compostos, sais ou solvatos; (c) a utilização desses compostos, sais ou solvatos em terapia; (d) métodos terapêuticos de tratamento utilizando esses compostos, sais ou solvatos; e (e) processos e inter-mediários úteis para a síntese desses compostos.
BR112021023834A 2019-06-05 2020-06-03 Inibidores de dopamina-b-hidroxilase BR112021023834A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908044.9A GB201908044D0 (en) 2019-06-05 2019-06-05 Dopamine-B-Hydroxylase inhibitors
PCT/PT2020/050022 WO2020246903A1 (en) 2019-06-05 2020-06-03 Dopamine-β-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
BR112021023834A2 true BR112021023834A2 (pt) 2022-01-04
BR112021023834A8 BR112021023834A8 (pt) 2023-02-28

Family

ID=67385676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023834A BR112021023834A8 (pt) 2019-06-05 2020-06-03 Inibidores de dopamina-b-hidroxilase

Country Status (14)

Country Link
US (1) US20220267331A1 (pt)
EP (1) EP3980421A1 (pt)
JP (1) JP2022535423A (pt)
KR (1) KR20220044246A (pt)
CN (1) CN113966333A (pt)
AR (1) AR119093A1 (pt)
AU (1) AU2020287821A1 (pt)
BR (1) BR112021023834A8 (pt)
CA (1) CA3142348A1 (pt)
GB (1) GB201908044D0 (pt)
IL (1) IL288323A (pt)
MX (1) MX2021014941A (pt)
TW (1) TW202112780A (pt)
WO (1) WO2020246903A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9605145A (es) 1994-04-26 1997-12-31 Syntex Inc Derivados de benzocicloalquilazoletina como inhibidores de beta-hidroxilasa de dopamina.
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JOP20190050A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
AU2018379646A1 (en) 2017-12-04 2020-06-11 BIAL - PORTELA & Cª, S.A. Dopamine-B-hydroxylase inhibitors

Also Published As

Publication number Publication date
MX2021014941A (es) 2022-01-24
KR20220044246A (ko) 2022-04-07
CN113966333A (zh) 2022-01-21
TW202112780A (zh) 2021-04-01
GB201908044D0 (en) 2019-07-17
AU2020287821A1 (en) 2022-01-06
WO2020246903A1 (en) 2020-12-10
AR119093A1 (es) 2021-11-24
BR112021023834A8 (pt) 2023-02-28
CA3142348A1 (en) 2020-12-10
IL288323A (en) 2022-01-01
EP3980421A1 (en) 2022-04-13
US20220267331A1 (en) 2022-08-25
JP2022535423A (ja) 2022-08-08

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112019004248A2 (pt) inibidores da dopamina-b-hidroxilase
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
EA202193015A1 (ru) Ингибиторы cdk
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
PH12016502353A1 (en) Pharmaceutical composition
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
BR112017000584A2 (pt) inibidores da aldosterona sintase
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
BR112021023834A2 (pt) Inibidores de dopamina-b-hidroxilase
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112018076564A2 (pt) uso de um composto de fórmula i, composições farmacêuticas, composto de fórmula i, usos de um composto ou um sal farmaceuticamente aceitável do mesmo, e compostos ou sais farmaceuticamente aceitáveis dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]